To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC).
Introduction
About 75% of patients with bladder cancer present with non-muscle-invasive bladder cancer (NMIBC) [1] . The initial management consists of transurethral resection of bladder tumour (TURBT), but even after complete resection, the risk of recurrence can be as high as 78% [2] . To prevent recurrences, the European Association of Urology (EAU) guidelines recommend an immediate intravesical instillation of chemotherapy in low-and intermediate-risk patients with previous low recurrence rate (≤1 recurrence/year) and with an expected European Organisation for Research and Treatment of Cancer (EORTC) recurrence score of <5 [2, 3] . The EORTC recurrence score is based on variables that predict recurrence and these include the number of tumours, tumour size, prior recurrence rate, tumour stage, presence of carcinoma in situ (CIS), and tumour grade [2] . The rationale for an immediate intravesical instillation of chemotherapy after TURBT is that the instillation eradicates floating tumour cells, which may otherwise reimplant into the bladder wall [4] . Furthermore, it has an ablative effect on residual tumour or small overlooked tumours.
The EAU guidelines state that the preferred time window for an immediate instillation is within 2 h after surgery [3] . This recommendation is based on animal studies [5] [6] [7] . In humans, there are only a few small studies that have analysed the impact of timing of an immediate instillation on the risk of recurrence [8] [9] [10] .
In the present study we questioned whether the efficacy of a very early instillation of intravesical chemotherapy (on the same day as the TURBT) was comparable to an early instillation (1 day after TURBT). Data were obtained from a multicentre, prospective randomised clinical trial that studied an immediate (<24 h) vs delayed (2 weeks after TURBT) intravesical instillation of mitomycin C (MMC) in 2 234 patients with NMIBC [11] .
Patients and Methods

Original Trial
The results of the trial from which the data were obtained were published previously [11] . The trial was approved by the Institutional Review Board. Briefly, between 1998 and 2003 patients with NMIBC were randomised for either an immediate (<24 h after TURBT) or a delayed (2 weeks after TURBT) instillation of MMC. The instillation was kept in the bladder for a minimum of 1 h, but no longer than 2 h. Thereafter, based on histology, patients were categorised into three groups and received a total of one, nine or 15 instillations of 40 mg MMC in 50 mL saline 0.9%. Patients with primary, solitary Ta/T1 tumours of grade 1 or 2 were assigned to receive one instillation. Patients with primary, solitary T1 tumours of grade 3 or recurrent, solitary Ta/T1 tumours of grade 1-3 were assigned to a total of nine instillations. Patients with multiple tumours and/or CIS were assigned to a total of 15 instillations. The study showed that an immediate instillation (<24 h after TURBT) results in a reduction of the recurrence risk by 27% (hazard ratio [HR] 0.73, 95% CI 0.63-0.85; P < 0.001).
Present Analysis
Only patients that were randomised for an immediate (<24 h) instillation of MMC after TURBT were included in the present analysis. In the original trial, 1 048 patients were randomised to receive an instillation of MMC within 24 h after TURBT. Of these patients, 359 (34%) patients received an instillation of MMC on the day of TURBT (very early instillation, Day-0 group) and 582 (56%) 1 day after TURBT (early instillation, Day-1 group). A total of 106 (10%) patients received an instillation at >1 day after TURBT; they were excluded from this analysis. In one patient the timing of the instillation was unknown, leaving a total of 941 patients.
Follow-up and Endpoint
A cystoscopy was performed every 3 months in the first year, and every 6 months thereafter.
Tumours confirmed by histology after TURBT, as well as small lesions that appeared malignant clinically and that were electrocauterised in an outpatient setting were classified as recurrences. Time-to-recurrence was defined as the time between TURBT and the date of first positive biopsy/ electrocauterisation. Adverse events were recorded at each visit.
Statistical Analysis
Categorical data were summarised with frequency and percentage, continuous data with mean, median, first and third quartiles. The chi-squared test was used to compare categorical data between groups, the independent samples t-test was used to compare means of continuous data between groups.
Time to recurrence was analysed using the Kaplan-Meier method [12] . Kaplan-Meier curves were curtailed at 10 years of follow-up. Patients lost to follow-up without an event of interest, were censored at the last date of follow-up. Patients who died were also censored, as NMIBC is not a lethal disease and the death of patients without a recurrence is unlikely to be related to the NMIBC. Kaplan-Meier curves were constructed for each study arm (Day-0 and Day-1 instillation) and the difference in time to recurrence was tested using the log-rank test. Furthermore, the difference in time to recurrence between the Day-0-and Day-1-instillation groups was analysed using a multivariable Cox proportionalhazard model to correct for possible confounders, using a forward stepwise selection. Variables that were tested: gender, age, tumour stage (Ta-T1), number of tumours (single/ multiple), tumour grade, preceding recurrence rate (≤1 recurrence per year/>1 recurrence per year), the presence of CIS (yes/no), and the number of scheduled adjuvant instillations (one, nine or 15). Factors were added to the model in case of statistical significance, together with the variable Day-0/Day-1 instillation.
Tumour size was missing in a large number of patients (n = 482). To assess the effect of these missing data on the difference in time to recurrence between the Day-0-/Day-1-instillation groups, a sensitivity analysis was conducted that included only the patients with a known tumour size. Additionally, the time to recurrence of patients with an unknown tumour size was compared to the time to recurrence of patients with a known tumour size using the Kaplan-Meier method and log-rank test, as well as the multivariable Cox proportional-hazard model to correct for the number of assigned adjuvant instillations.
Analyses were performed with Statistical Package for the Social Sciences (SPSS â ) software (version 22.0; SPSS Inc., IBM Corp., Armonk, NY, USA). Tests were two-sided and the significance level was set at P < 0.05 for all tests.
Results
Baseline characteristics of the included patients are shown in Table 1 . The number of tumours and the number of assigned adjuvant instillations significantly differed between the two groups. The median (interquartile range [IQR]) follow-up for patients without a recurrence was 33 (17-54) months in the Day-0-instillation group and 34 (19-51) months in the Day-1-instillation group. After total follow-up, 99/359 of the patients developed a recurrence in the Day-0-instillation group and 157/582 in the Day-1-instillation group.
The time to recurrence did not significantly differ between the two groups (log-rank test, P = 0.99, Fig. 1 ). In the 572 © 2018 The Authors BJU International © 2018 BJU International multivariable Cox regression analysis using forward stepwise selection, only the number of scheduled adjuvant instillations was statistically significant and thus added to the model, which included the Day-0-/Day-1-instillation group variable. In the final multivariable model, the time to recurrence did not significantly differ between the Day-0-and the Day 1-instillation groups (HR 1.05, 95% CI 0.81-1.35; P = 0.74).
Sensitivity Analysis
For the sensitivity analysis, patients with an unknown tumour size were excluded (n = 482), leaving 459 evaluable patients. From these patients, 57/204 patients developed a recurrence in the day-0-instillation group and a total of 61/255 in the day-1-instillation group. Time to recurrence did not significantly differ between the two groups (log-rank, P = 0.62, Fig. 2) . In the multivariable model, which included the variable Day-0-/Day-1 instillation, as well as the number of adjuvant instillations, the time to recurrence also did not differ significantly between the Day-0-and Day-1-instillation group (HR 1.00, 95% CI 0.69-1.44; P = 0.98, multivariable). Furthermore, the time to recurrence did not differ significantly between patients with a known or unknown tumour size (log-rank P = 0.60 and HR 0.96, 95% CI 0.75-1.23; P = 0.74, multivariable).
Adverse Events
A total of 84/359 (23%) of the patients in the day-0 group had an adverse event. In the day-1-instillation group, a total of 148/582 (25%) patients had an adverse event. This difference was not statistically significant (23% vs 25%, P = 0.5). Most reported adverse events were irritative urinary symptoms (22/941 patients, 2.3%) and exanthema (59/941 patients, 6.3%). Four patients (0.4%) were suspected of MMC Recurrence-free survival (%) Log-rank P = 0.99 extravasation (day-0 group, one; day-1 group, three). Surgical intervention was not considered necessary in any of the cases.
Discussion
In the present study, we demonstrated that the time to recurrence of NMIBC does not differ between patients who receive an instillation of MMC on the day of TURBT, and those who receive an intravesical instillation of MMC 1 day after TURBT. This is of clinical importance, as patients who did not receive an instillation on the day of TURBT for practical reasons might still benefit from an instillation the next day. However, delaying an instillation to 2 weeks after TURBT does result in a statistically significant difference in time to recurrence, as was demonstrated in our previous study [11] .
Another finding of the present study was that the only variable that predicted recurrence was the number of instillations, whereas the strongest predictor for recurrence according to the EORTC recurrence score is the number of tumours [2] . A possible explanation for this discrepancy could be that the number of adjuvant installations in the original trial was dependent of the tumour characteristics. Chemotherapeutic instillations decrease the risk of recurrence and patients with multiple tumours were assigned to the highest number of instillations. Therefore, it is most likely that the number of instillations have reduced the prognostic value of multiple tumours to non-significant on multivariable analysis.
The number of tumours and the number of instillations differed significantly between the two groups. The number of instillations and the number of patients with multiple tumours were higher for the Day-1-instillation group. On the one hand, multiple tumours increase the risk of recurrence; on the other hand more adjuvant instillations decrease the risk of recurrence. For this reason these variables were included as potential confounders in a stepwise multivariable model. After correcting for the number of adjuvant instillations there still was no (significant) difference in time to recurrence between the Day-0-and Day-1-instillation groups.
As of yet, the optimal time frame for an immediate instillation in patients with NMIBC has not been studied in a prospective setting. The time frame of 2 h for an immediate instillation, which is recommended in the EAU guidelines [3] stems from the results of in vitro and animal studies [5, 13] . These studies showed that implantation of tumour cells occurs after a few hours [5, 13] .
Pan et al. [14] studied the effect of timing of an instillation of thiotepa on murine bladder tumour cell implantation in 172 mice. They were treated with an immediate, a 1-h delayed or a 24-h delayed instillation of thiotepa. Furthermore, a control group was treated with an instillation not containing any thiotepa. A decreased implantation rate in mice treated with an immediate or a 1-h delayed treatment (3.4% and 6.5%, respectively) compared with the control group (43%) was reported. A 24-h delayed instillation did not result in a statistically significant difference in implantation rate (26.9% vs 43% in the control group).
Besides our present study, there are a few small studies in which the effect of timing of an immediate instillation on the risk of recurrence in human is analysed. Gudj onsson et al. [8] performed a prospective multicentre study in which 305 patients with primary/recurrent low-or intermediate-risk tumours were randomised to receive an intravesical instillation with either epirubicin or saline within 24 h. A total of 25 patients that were randomised for the epirubicin arm, received the instillation 1 day after TURBT instead of on the day of TURBT. No difference in recurrence-free survival was noted between the Day-0 and Day-1 groups. In a prospective, randomised study Hendricksen et al. [9] compared the efficacy of three schedules of epirubicin in intermediate-and high-risk patients. One arm of the study included an instillation <48 h after TURBT. At total of 168 patients received the instillation within 24 h and 74 patients within 24-48 h after TURBT. After 5 years of follow-up, no difference in recurrence-free rates was found between the <24-h and the 24-48-h instillation groups (41.5% vs 47.3%, respectively; P = 0.40).
Only one study, conducted by Kaasinen et al. [10] , demonstrated a significant difference in recurrence risk for patients treated with a very early instillation compared to patients treated with an early instillation. The effect of timing of an immediate intravesical instillation of MMC was investigated in 137 patients who underwent TURTB for recurrent NMIBC. Patient data were collected from a previously conducted trial in which patients were treated with MMC and thereafter randomised for either a schedule of BCG or BCG and interferon a instillations. They found that patients who received an instillation of MMC 1 day after TURBT had a more than a two-fold risk of recurrence as compared to those who received the instillations on the day of TURBT (HR 2.37, 95% CI 1.40-4.01; P = 0.001). The results of that study should be interpreted with some caution, as only 33 patients were included in the Day-1 group.
To our knowledge, our present study is the largest study in which the effect of timing of an immediate instillation with MMC on the time to recurrence has been analysed. Nevertheless, there are a number of limitations. Firstly, the present study was not designed for an early-vs very-early instillation analysis and the use of postoperative irrigation with saline was not registered. Non-randomised comparisons have shown that postoperative irrigation may have an effect on the likelihood of recurrence [15] . Secondly, in the original 574 © 2018 The Authors BJU International © 2018 BJU International trial the timing of the instillation was registered in days and not in hours. Hence, we could not assess whether an instillation that was administered immediately after TURBT (e.g. in the operating theatre) reduces the risk of recurrence compared to an instillation a few hours later. Thirdly, the tumour size was unknown in 482 patients and therefore tumour size was not included as a variable. However, leaving patients with unknown tumour size out of the analysis also did not result in a significant difference in the time to recurrence between the Day-0-and Day-1-instillation groups (HR 1.00, 95% CI 0.69-1.44; P = 0.98). Furthermore, there was no significant difference in time to recurrence between patients with known and unknown tumour size (P = 0.60).
Conclusions
Administering an immediate instillation of MMC on the same day or 1 day after TURBT in patients with NMIBC does not result in a significant difference in the time to recurrence. Hence, patients whom do not receive an instillation on the day of TURBT might still benefit from an instillation that is administered the next day.
